News By Company | Xenon Pharmaceuticals Inc. News on T-Net

1 - 10 of 43 Results

Xenon Pharmaceuticals Announces Collaboration with Researchers at Icahn School of Medicine at Mount Sinai to Conduct a Phase 2 Study of XEN1101

Burnaby, BC, March 23, 2021--Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, has announced a collaboration with the Icahn School of Medicine at Mount Sinai (Mount Sinai) to facilitate an investigator-sponsored Phase 2 proof-of-concept, randomized, parallel-arm, placebo-controlled clinical trial of XEN1101 for the treatment of major depressive disorder (MDD) and anhedonia, which is an inability to feel pleasure.

Vancouver-based Biopharmaceutical Company Xenon Announces Closing of $115 Million Financing

Burnaby, BC, March 17, 2021--Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a Vancouver-based clinical stage biopharmaceutical company, has announced the closing of its underwritten public offering of 5,135,135 common shares, which includes 810,810 shares sold upon the full exercise of the underwriters' option to purchase additional shares, and pre-funded warrants to purchase 1,081,081 common shares.

Xenon Pharmaceuticals Reports 2020 Financial Results and Provides Corporate Update

Burnaby, BC, March 2, 2021--Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, reported financial results for the year ended December 31, 2020 and provided a corporate update.

Xenon Pharmaceuticals Outlines Key Milestone Opportunities and Planned Leadership Transition in 2021

Burnaby, BC, January 19, 2021--Xenon Pharmaceuticals Inc.(Nasdaq:XENE), a neurology-focused biopharmaceutical company, outlined its key milestone opportunities and plans for a leadership transition in 2021, with all changes anticipated to take effect in June 2021 at the time of the Company's annual meeting of shareholders.

Xenon Pharmaceuticals Provides Updates on Neurology Pipeline Programs

Burnaby, BC, December 16, 2020--Xenon Pharmaceuticals Inc.(Nasdaq:XENE), a neurology-focused biopharmaceutical company, announced updates on its proprietary and partnered neurology programs at AES2020, the virtual Annual Meeting of the American Epilepsy Society.

Xenon Pharmaceuticals Receives FDA Feedback and is on Track to Initiate XEN496 Phase 3 Clinical Trial for the Treatment of KCNQ2-DEE

Burnaby, BC, October 9, 2020--Xenon Pharmaceuticals Inc.(Nasdaq:XENE), a neurology-focused biopharmaceutical company, provided regulatory updates on its proprietary pediatric neurology program, XEN496, a Kv7 potassium channel modulator that is a proprietary pediatric formulation of the active ingredient ezogabine being developed for the treatment of KCNQ2 developmental and epileptic encephalopathy (KCNQ2-DEE).

Xenon Pharmaceuticals Appoints Dr. Chris Von Seggern as Chief Commercial Officer

Burnaby, BC, August 25, 2020--Xenon Pharmaceuticals Inc.(Nasdaq:XENE), a neurology-focused biopharmaceutical company, announced the appointment of Dr. Chris Von Seggern as Chief Commercial Officer, effective immediately.

Xenon Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update

Burnaby, BC, August 13, 2020--Xenon Pharmaceuticals Inc.(Nasdaq:XENE), a neurology-focused biopharmaceutical company, reported its financial results for second quarter ended June 30, 2020 and provided a corporate update.

Xenon Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate Update

Burnaby, BC, May 28, 2020--Xenon Pharmaceuticals Inc.(Nasdaq:XENE), a neurology-focused biopharmaceutical company, reported its financial results for first quarter ended March 31, 2020 and provided a corporate update.

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Burnaby, BC, March 31, 2020--Xenon Pharmaceuticals Inc.(Nasdaq:XENE), a clinical stage biopharmaceutical company, announced equity inducement grants to eight new non-officer employees consisting of an aggregate of 63,200 share options.